Redirecting to https://www.wallstreet-online.de/nachricht/20359338-summit-therapeutics-announces-submission-of-biologics-license-application-bla-to-u-s-fda-seeking-approval-for-ivonescimab-combination-with-chemotherapy-2l-treatment-of-patients-with-egfrm-nsclc